Anaphylaxis, Chronic Spontaneous Urticaria (CSU), Healthy Control, Hereditary Alpha-Tryptasemia, Mastocytosis, Medication Allergy, Type I Allergy, Venom Allergy, X-linked Agammaglobulinaemia
Conditions
Brief summary
The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of anaphylaxis, patients with mastocytosis, patients with hereditary alpha tryptasemia, patients with X-linked agammaglobulinemia (XLA), and patients undergoing desensitization for venom or medication allergy.
Interventions
OTHERBlood sample collection
Blood sample collection
Sponsors
KU Leuven
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing) * Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU)
Exclusion criteria
* Absence of informed consent * Age \< 18 years old
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of IgE proteoforms | 4 years |
Countries
Belgium
Outcome results
None listed